 AbCellera Biologics reported Q2 numbers that were not all that impressive; however, the news of the commercialization agreement its partner Lilly inked has driven shares to near YTD highs. The commercialization plan looks to provide AbCellera with continued non-dilutive funding to further build its now 1 billion cash war chest. 